InvestWiser

Orexo AB

ORXNasdaq StockholmHealthcareMarket value 56 m SEK
1.01SEK +11.9%
last day · Price as of 18 November 2026

The answer first

Does Orexo beat the market?

No, Orexo has not beaten the market over the last year.

Orexo−96.3%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 47% of Nordic stocks

    • Quality67
    • Value85
    • Trend1

    No. 65 of 195 in healthcare

Max for seven days

Follow Orexo with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Orexo

From today, at a price of 1.01 SEK. Write why you follow Orexo, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Orexo

Your first answer is free, no account needed.

Do you own Orexo, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Orexo and a few more. Free, no card.

Past year against the exchange and Super Stock
Orexo−96.3%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Orexo has fallen 96.3% over the past year, including dividends.
  • Overall, Orexo ranks better than 47% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 98.0%. The price is 99.4% below its peak now.

What do analysts think of Orexo?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

47

Quality, value and trend together. Better than 47% of Nordic stocks.

No. 65 of 195 in healthcare

Quality67
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 92 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity2.79
  • Asset turnoverSales divided by everything the company owns0.03
  • Return on equityProfit divided by equity−89.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value85
The price · Valuation: the multiples

High Low price: you pay little for what the company earns and owns.

No. 12 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.2
  • P/SPrice divided by sales2.8
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend1
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 197 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−92.7%
  • 6 months−94.9%
  • 9 months−96.2%
  • 12 months−96.3%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−81.4%
3 years, per year
−59.6%
5 years, per year
−49.6%
10 years, per year
−31.4%
Largest fall, 3 years
−98.0%
From a peak to the bottom
From the peak now
−99.4%
How far the price is from the peak
Volatility, 1 year
115.7%
How much the price swings over a year
Beta, 1 year
0.26
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Orexo

5 funds we follow own Orexo. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About Orexo

Orexo AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 55 employees.

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori.

See the full analysis of Orexo.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market